NewsBenzingaオブシディアン・セラピューティクス、がん免疫療法学会で、免疫チェックポイント阻害薬抵抗性の進行性メラノーマ患者を対象とした第1相試験およびアムソキゲン・オートロイセルの第1/2相Agni-01多施設共同試験における最新データを発表へ オブシディアン・セラピューティクス、がん免疫療法学会で、免疫チェックポイント阻害薬抵抗性の進行性メラノーマ患者を対象とした第1相試験およびアムソキゲン・オートロイセルの第1/2相Agni-01多施設共同試験における最新データを発表へ Benzinga 2026.11.06 14:10 (GMT+0) Open on Benzinga Other news Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Anthony Scaramucci Says Trump Could Abandon Republicans After Midterm Losses to Focus on 'Money' With Jared Kushner Cloudastructure (CSAI) Shares Jump 52% After-Hours: What Investors Should Know Trump Administration ‘Monitoring’ All Threats As Iran Reportedly Explores Dirty Bomb, Chemical Weapons Attack on US: Report Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Former Robinhood Software Engineer Admits Using Confidential Information to Trade Crypto Perpetuals, Agrees to Forfeit Proceeds
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Anthony Scaramucci Says Trump Could Abandon Republicans After Midterm Losses to Focus on 'Money' With Jared Kushner
Trump Administration ‘Monitoring’ All Threats As Iran Reportedly Explores Dirty Bomb, Chemical Weapons Attack on US: Report
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory
Former Robinhood Software Engineer Admits Using Confidential Information to Trade Crypto Perpetuals, Agrees to Forfeit Proceeds